Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study
Research output: Contribution to journal › Journal article › Research › peer-review
Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.
Original language | English |
---|---|
Journal | Journal of Neuroimmunology |
Volume | 326 |
Pages (from-to) | 19-27 |
ISSN | 0165-5728 |
DOIs | |
Publication status | Published - Jan 2019 |
- Anti-drug antibodies, Bridging ELISA, Interferon-beta, Luciferase-based bioassay, Multiple sclerosis, Neutralizing antibodies
Research areas
ID: 241938547